{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:20:28Z","timestamp":1755598828328,"version":"3.40.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04160-8","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T22:47:52Z","timestamp":1743288472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of intravenous immunoglobulin on kidney functions and thromboembolic events in dermatology patients"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1767-4960","authenticated-orcid":false,"given":"Ceylan","family":"Avc\u0131","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2753-3432","authenticated-orcid":false,"given":"Ayg\u00fcn","family":"Talibova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-3969","authenticated-orcid":false,"given":"Ozlem","family":"Ozbagcivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7903-1106","authenticated-orcid":false,"given":"Cihan","family":"Heybeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2927-9052","authenticated-orcid":false,"given":"Emel","family":"Fetil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"4160_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/ddg.13013","volume":"15","author":"A Enk","year":"2017","unstructured":"Enk A, Hadaschik E, Eming R et al (2017) European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. J Dtsch Dermatol Ges 15:228\u2013241. https:\/\/doi.org\/10.1111\/ddg.13013","journal-title":"J Dtsch Dermatol Ges"},{"key":"4160_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/ajd.14024","volume":"64","author":"JK Nguyen","year":"2023","unstructured":"Nguyen JK, Holmes Z, Kelly RI (2023) Intravenous immunoglobulin treatment for refractory pyoderma gangrenosum. Australas J Dermatol 64:221\u2013228. https:\/\/doi.org\/10.1111\/ajd.14024","journal-title":"Australas J Dermatol"},{"key":"4160_CR3","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/ddg.13389","volume":"15","author":"JHO Hoffmann","year":"2017","unstructured":"Hoffmann JHO, Enk AH (2017) High-dose intravenous immunoglobulins for the treatment of dermatological autoimmune diseases. J Dtsch Dermatol Ges 15:1211\u20131226. https:\/\/doi.org\/10.1111\/ddg.13389","journal-title":"J Dtsch Dermatol Ges"},{"key":"4160_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/ijd.14143","volume":"58","author":"SA Grando","year":"2019","unstructured":"Grando SA (2019) Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs. Int J Dermatol 58:114\u2013125. https:\/\/doi.org\/10.1111\/ijd.14143","journal-title":"Int J Dermatol"},{"key":"4160_CR5","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.thromres.2014.03.046","volume":"133","author":"E Ram\u00edrez","year":"2014","unstructured":"Ram\u00edrez E, Romero-Garrido JA, L\u00f3pez-Granados E et al (2014) Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study. Thromb Res 133:1045\u20131051. https:\/\/doi.org\/10.1016\/j.thromres.2014.03.046","journal-title":"Thromb Res"},{"key":"4160_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2340\/00015555-1471","volume":"93","author":"V Seidling","year":"2013","unstructured":"Seidling V, Hoffmann JH, Enk AH, Hadaschik EN (2013) Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm Venereol 93:346\u2013349. https:\/\/doi.org\/10.2340\/00015555-1471","journal-title":"Acta Derm Venereol"},{"key":"4160_CR7","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/exd.14829","volume":"32","author":"N Kianfar","year":"2023","unstructured":"Kianfar N, Dasdar S, Daneshpazhooh M et al (2023) A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy. Exp Dermatol 32:934\u2013944. https:\/\/doi.org\/10.1111\/exd.14829","journal-title":"Exp Dermatol"},{"key":"4160_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.intimp.2005.11.015","volume":"6","author":"DJ Hamrock","year":"2006","unstructured":"Hamrock DJ (2006) Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 6:535\u2013542. https:\/\/doi.org\/10.1016\/j.intimp.2005.11.015","journal-title":"Int Immunopharmacol"},{"key":"4160_CR9","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2215\/CJN.00500108","volume":"3","author":"G Boll\u00e9e","year":"2008","unstructured":"Boll\u00e9e G, Anglicheau D, Loupy A et al (2008) High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients. Clin J Am Soc Nephrol 3:1461\u20131468. https:\/\/doi.org\/10.2215\/CJN.00500108","journal-title":"Clin J Am Soc Nephrol"},{"key":"4160_CR10","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/mus.25693","volume":"56","author":"AA Levine","year":"2017","unstructured":"Levine AA, Levine TD, Clarke K, Saperstein D (2017) Renal and hematologic side effects of long-term intravenous immunoglobulin therapy in patients with neurologic disorders. Muscle Nerve 56:1173\u20131176. https:\/\/doi.org\/10.1002\/mus.25693","journal-title":"Muscle Nerve"},{"key":"4160_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"},{"key":"4160_CR12","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1345\/aph.1K198","volume":"41","author":"HM G\u00fcrcan","year":"2007","unstructured":"G\u00fcrcan HM, Ahmed AR (2007) Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid. Ann Pharmacother 41:1604\u20131610. https:\/\/doi.org\/10.1345\/aph.1K198","journal-title":"Ann Pharmacother"},{"key":"4160_CR13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.semarthrit.2004.06.003","volume":"34","author":"H Orbach","year":"2004","unstructured":"Orbach H, Tishler M, Shoenfeld Y (2004) Intravenous immunoglobulin and the kidney\u2013a two-edged sword. Semin Arthritis Rheum 34:593\u2013601. https:\/\/doi.org\/10.1016\/j.semarthrit.2004.06.003","journal-title":"Semin Arthritis Rheum"},{"key":"4160_CR14","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1093\/ajhp\/zxac139","volume":"79","author":"RH Kobayashi","year":"2022","unstructured":"Kobayashi RH, Rigas MT (2022) Immune globulin therapy and kidney disease: overview and screening, monitoring, and management recommendations. Am J Health Syst Pharm 79:1415\u20131423. https:\/\/doi.org\/10.1093\/ajhp\/zxac139","journal-title":"Am J Health Syst Pharm"},{"key":"4160_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.anai.2016.11.009","volume":"118","author":"AS Kim","year":"2017","unstructured":"Kim AS, Broide DH (2017) Acute renal dysfunction caused by nonsucrose intravenous immunoglobulin in common variable immunodeficiency. Ann Allerg Asthma Immunol 118:231\u2013233. https:\/\/doi.org\/10.1016\/j.anai.2016.11.009","journal-title":"Ann Allerg Asthma Immunol"},{"key":"4160_CR16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/tri.12833","volume":"29","author":"Y Luque","year":"2016","unstructured":"Luque Y, Anglicheau D, Rabant M et al (2016) Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study. Transpl Int 29:1205\u20131215. https:\/\/doi.org\/10.1111\/tri.12833","journal-title":"Transpl Int"},{"key":"4160_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2230.2008.02809.x","volume":"34","author":"MD Mignogna","year":"2009","unstructured":"Mignogna MD, Fortuna G, Leuci S et al (2009) Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases. Clin Exp Dermatol 34:145\u2013150. https:\/\/doi.org\/10.1111\/j.1365-2230.2008.02809.x","journal-title":"Clin Exp Dermatol"},{"key":"4160_CR18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ajh.24358","volume":"91","author":"EM Ammann","year":"2016","unstructured":"Ammann EM, Haskins CB, Fillman KM et al (2016) Intravenous immune globulin and thromboembolic adverse events: a systematic review and meta-analysis of RCTs. Am J Hematol 91:594\u2013605. https:\/\/doi.org\/10.1002\/ajh.24358","journal-title":"Am J Hematol"},{"key":"4160_CR19","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamadermatol.2023.1105","volume":"159","author":"ET Rotrosen","year":"2023","unstructured":"Rotrosen ET, Zahedi Niaki O, Kassamali B et al (2023) Intravenous immunoglobulin and dermatomyositis-associated venous thromboembolism. JAMA Dermatol 159:666\u2013667. https:\/\/doi.org\/10.1001\/jamadermatol.2023.1105","journal-title":"JAMA Dermatol"},{"issue":"6","key":"4160_CR20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1159\/000529110","volume":"184","author":"M Jiang","year":"2023","unstructured":"Jiang M, Kimber JS, Gupta A et al (2023) Adverse reactions associated with intravenous immunoglobulin administration in the treatment of neurological disorders: a systematic review. Int Arch Allergy Immunol 184(6):513\u2013528. https:\/\/doi.org\/10.1159\/000529110","journal-title":"Int Arch Allergy Immunol"},{"key":"4160_CR21","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","volume":"155","author":"I Marie","year":"2006","unstructured":"Marie I, Maurey G, Herv\u00e9 F et al (2006) Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 155:714\u2013721. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07390.x","journal-title":"Br J Dermatol"},{"key":"4160_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jaad.2017.01.059","volume":"77","author":"YA Leshem","year":"2017","unstructured":"Leshem YA, Atzmony L, Dudkiewicz I et al (2017) Venous thromboembolism in patients with pemphigus: a cohort study. J Am Acad Dermatol 77:256\u2013260. https:\/\/doi.org\/10.1016\/j.jaad.2017.01.059","journal-title":"J Am Acad Dermatol"},{"key":"4160_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00403-020-02099-6","volume":"313","author":"MS Shaheen","year":"2021","unstructured":"Shaheen MS, Silverberg JI (2021) Association of inflammatory skin diseases with venous thromboembolism in US adults. Arch Dermatol Res 313:281\u2013289. https:\/\/doi.org\/10.1007\/s00403-020-02099-6","journal-title":"Arch Dermatol Res"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04160-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04160-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04160-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T03:13:56Z","timestamp":1743304436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04160-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4160"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04160-8","relation":{},"ISSN":["1432-069X"],"issn-type":[{"type":"electronic","value":"1432-069X"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"9 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict interest"}}],"article-number":"636"}}